中国药理学与毒理学杂志2024，Vol.38Issue(1)：56-69,14.DOI:10.3867/j.issn.1000-3002.2024.01.007
PD-1/PD-L1单抗药物抗肿瘤免疫治疗相关不良反应及超进展疾病研究进展
Advances in treatment of immune-related adverse reactions and hyperprogressive diseases associated with antitumor immunotherapy with PD-1/PD-L1 monoclonal antibody drugs
摘要
Abstract
There have been breakthroughs in the development and clinical application of immuno-therapeutic agents in recent years.As the clinical targets of second-generation immune checkpoint inhibitors(ICIs),programmed death-1(PD-1)and its ligand(programmed death-ligand 1,PD-L1)have become one of the hot spots in drug discovery.The Food and Drug Administration of the USA and National Medical Products Administration in China have approved a variety of PD-1/PD-L1 monoclonal antibody drugs(such as nivolumab,pembrolizumab and atezolizumab),which are marketed for the treatment of small-cell lung cancer,rectal cancer,colon cancer,and melanoma,among other diseases.However,in the clinical application of PD-1/PD-L1 monoclonal antibody drugs,it is found that they can cause different degrees of immune-related adverse reactions in the lung,liver,kidney,gastrointestinal system,endocrine system and skin,and even the emergence of hyperprogressive disease.Effective monitoring and management of clinical applications of PD-1/PD-L1 monoclonal antibody drugs and rational use of some drugs can improve the immunotherapy process and reduce the effects of adverse reactions and hyperprogressive diseases in patients under immunotherapy.关键词
免疫治疗/程序性死亡受体1/程序性死亡受体配体1/免疫相关不良反应/超进展疾病Key words
immunotherapy/programmed death-1/programmed death-ligand 1/immune related adverse reactions/hyperprogression disease分类
医药卫生引用本文复制引用
王鹏焱,林子又,朱凯,张小雷..PD-1/PD-L1单抗药物抗肿瘤免疫治疗相关不良反应及超进展疾病研究进展[J].中国药理学与毒理学杂志,2024,38(1):56-69,14.基金项目
国家自然科学基金(82273958) （82273958）
吉林省科技发展计划(20230204063YY) （20230204063YY）
吉林省科技发展计划(20210204055YY) National Natural Science Foundation of China(82273958) （20210204055YY）
Jilin Province Science and Technology Development Project(20230204063YY) （20230204063YY）
and Jilin Province Science and Technology Development Project(20210204055YY) （20210204055YY）
